ONCOZ Share Price Performance
SEK 5.12
-0.48 (-8.57%)
Price SEK 5.12
Share Pricen/a
No recently updated narratives available.
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.